SecBot SecBot
SECBOTREPLAY Home › Report › NVCR

NVCR · NovoCure's DEFA14A filing is a definitive proxy statement for its 2026…

NovoCure Ltd · DEFA14A filed Apr 20, 2026 at 16:06 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 20, 2026 at 16:06 ET

NovoCure's DEFA14A filing is a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on director elections, auditor ratification, executive compensation, and an amended incentive plan. This follows recent board changes, suggesting the vote is routine. The filing is neutral with low impact.

  • Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • Shareholders will vote on 11 director nominees, auditor ratification, executive compensation, and an amended incentive plan.
  • Recent 8-K filing (11 days prior) reported a compensation change for an executive officer.
  • No activist campaign or dissident slate is present; this is a management solicitation.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access